SCHEMBL17124238

SCHEMBL17124238

CC1(C)C2CC[C@]3(C)C(CCC4C5[C@H](C(O)CO)CC[C@]5(C)CC[C@]43C)[C@@]2(C)CC[C@@H]1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.62
TOP2A P11388 2/20 0.62
CES2 O00748 1/20 0.62
CES1 P23141 1/20 0.62
SLC10A1 Q14973 1/20 0.62
GPBAR1 Q8TDU6 5/20 0.60
PRKCD Q05655 1/20 0.56
USP2 O75604 2/20 0.53
LMNA P02545 2/20 0.53
HIF1A Q16665 2/20 0.53
NT5E P21589 2/20 0.53
RELA Q04206 1/20 0.53
NR1H4 Q96RI1 1/20 0.52
RORC P51449 2/20 0.49
ALB P02768 2/20 0.48
AKR1B10 O60218 1/20 0.48
POLB P06746 1/20 0.48
GLI1 P08151 1/20 0.48
AKR1B1 P15121 1/20 0.48
DPP4 P27487 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13403268 0.87 SLC10A1 (0.73) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL13384623 0.87 SLC10A1 (0.73) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL476920 0.87 SLC10A1 (0.73) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL476921 0.87 SLC10A1 (0.73) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL15713932 0.85 GPBAR1 (0.82) PTPN1CES2CES1SLC10A1GPBAR1
SCHEMBL14134573 0.80 SLC10A1 (0.66) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL19429580 0.79 PTPN1 (0.78) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL30128636 0.79 PTPN1 (0.78) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL17124247 0.79 PTPN1 (0.72) PTPN1TOP2ACES2CES1SLC10A1
SCHEMBL19421421 0.79 PTPN1 (0.78) PTPN1TOP2ACES2CES1SLC10A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150272922-A1 Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof BIONICHE ANIMAL HEALTH USA, INC. 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272922-A1 Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof NR3C1, NR5A1, NR3C2 PTPN1 855/4885TOP2A 982/4885CES2 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.